TY - JOUR
T1 - Ivabradine for the treatment of cardiovascular diseases
AU - Ide, Tomomi
AU - ohtani, kisho
AU - Higo, Taiki
AU - Tanaka, Makoto
AU - Kawasaki, Yasushi
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
T.I. and K.O. belong to a department endowed by Actelion Pharmaceuticals. T.H. has no conflict of interest. M.T. and Y.K. are employees of Ono Pharmaceutical Co., Ltd. H.T. has received speakers’ bureau/honorarium from Otsuka Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Daiichi-Sankyo, Nippon Boehringer Ingelheim, Bayer Yakuhin, and Pfizer, research funds from Nippon Boehringer Ingelheim, Mitsubishi Tanabe Pharma, MSD, Daiichi-Sankyo, and Teijin Pharma, and consultation fees from Nippon Boehringer Ingelheim, Novartis Pharma K.K, Bayer Yakuhin, and Ono Pharmaceutical. H.T. is also a committee member of Phase II and III studies of ivabradine in Japanese patients with chronic HF.
Publisher Copyright:
© 2019, Japanese Circulation Society.
PY - 2019/2
Y1 - 2019/2
N2 - Higher heart rate (HR) is independently related to worse outcomes in various cardiac diseases, including hypertension, coronary artery disease, and heart failure (HF). HR is determined by the pacemaker activity of cells within the sinoatrial node. The hyperpolarization- activated cyclic nucleotide-gated (HCN) 4 channel, one of 4 HCN isoforms, generates the If current and plays an important role in the regulation of pacemaker activity in the sinoatrial node. Ivabradine is a novel and only available HCN inhibitor, which can reduce HR and has been approved for stable angina and chronic HF in many countries other than Japan. In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.
AB - Higher heart rate (HR) is independently related to worse outcomes in various cardiac diseases, including hypertension, coronary artery disease, and heart failure (HF). HR is determined by the pacemaker activity of cells within the sinoatrial node. The hyperpolarization- activated cyclic nucleotide-gated (HCN) 4 channel, one of 4 HCN isoforms, generates the If current and plays an important role in the regulation of pacemaker activity in the sinoatrial node. Ivabradine is a novel and only available HCN inhibitor, which can reduce HR and has been approved for stable angina and chronic HF in many countries other than Japan. In this review, we summarize the current knowledge of the HCN4 channel and ivabradine, including the function of HCN4 in cardiac pacemaking, the mechanism of action of If inhibition by ivabradine, and the pharmacological and clinical effects of ivabradine in cardiac diseases as HF, coronary artery disease, and atrial fibrillation.
UR - http://www.scopus.com/inward/record.url?scp=85060642797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060642797&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-18-1184
DO - 10.1253/circj.CJ-18-1184
M3 - Review article
C2 - 30606942
AN - SCOPUS:85060642797
SN - 1346-9843
VL - 83
SP - 252
EP - 260
JO - Circulation Journal
JF - Circulation Journal
IS - 2
ER -
